UPDATE: Jefferies Raises PT to $105 on Medivation on Zytiga Data

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Jefferies reiterates its Buy rating on Medivation (NASDAQ: MDVN) and raises its price target from $97 to $105. Jefferies notes, "On Saturday morning at ASCO, Dr. Charles Ryan from UCSF presented Ph III data reporting a strong OS benefit with Zytiga (~9 mos benefit if 33% improvement from 27 mos) in 1,088 chemo-naïve patients with CRPC. As a result of enzalutamide's broader AR inhibitory activity v. Zytiga, we believe enza could meet/beat the OS benefit observed in the '302 trial."MDVN closed at $82.68 on Friday.

27% profit every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!